Tevogen, Inc. (TVGN)
6.67
-0.31
(-4.44%)
USD |
NASDAQ |
Oct 05, 16:00
6.67
0.00 (0.00%)
After-Hours: 20:00
Tevogen Enterprise Value : 46.86M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 46.86M |
| October 01, 2026 | 45.75M |
| September 30, 2026 | 45.33M |
| September 29, 2026 | 45.88M |
| September 28, 2026 | 45.93M |
| September 25, 2026 | 48.01M |
| September 24, 2026 | 50.56M |
| September 23, 2026 | 50.39M |
| September 22, 2026 | 50.39M |
| September 21, 2026 | 48.78M |
| September 18, 2026 | 50.39M |
| September 17, 2026 | 49.97M |
| September 16, 2026 | 50.35M |
| September 15, 2026 | 50.14M |
| September 14, 2026 | 49.12M |
| September 11, 2026 | 48.48M |
| September 10, 2026 | 48.18M |
| September 09, 2026 | 48.39M |
| September 08, 2026 | 48.35M |
| September 04, 2026 | 48.39M |
| September 03, 2026 | 47.67M |
| September 02, 2026 | 47.67M |
| September 01, 2026 | 47.67M |
| August 31, 2026 | 46.86M |
| August 28, 2026 | 46.48M |
| Date | Value |
|---|---|
| August 27, 2026 | 45.88M |
| August 26, 2026 | 45.67M |
| August 25, 2026 | 46.82M |
| August 24, 2026 | 46.14M |
| August 21, 2026 | 45.88M |
| August 20, 2026 | 44.27M |
| August 19, 2026 | 44.48M |
| August 18, 2026 | 44.01M |
| August 17, 2026 | 45.16M |
| August 14, 2026 | 46.39M |
| August 13, 2026 | 45.12M |
| August 12, 2026 | 44.69M |
| August 11, 2026 | 45.46M |
| August 10, 2026 | 44.35M |
| August 07, 2026 | 44.69M |
| August 06, 2026 | 44.73M |
| August 05, 2026 | 46.31M |
| August 04, 2026 | 46.95M |
| August 03, 2026 | 47.03M |
| July 31, 2026 | 47.16M |
| July 30, 2026 | 45.75M |
| July 29, 2026 | 42.44M |
| July 28, 2026 | 40.95M |
| July 27, 2026 | 40.86M |
| July 24, 2026 | 36.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.834B |
| Oncolytics Biotech, Inc. | 74.98M |
| Sangamo Therapeutics, Inc. | 52.85M |
| Sarepta Therapeutics, Inc. | 2.106B |
| Anixa Biosciences, Inc. | 87.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.762M |
| Total Expenses (Quarterly) | 5.762M |
| EPS Diluted (Quarterly) | -1.525 |
| Earnings Yield | -87.42% |
| Normalized Earnings Yield | -87.68 |